Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 5INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3Gynecologic 3Gastrointestinal 3Thoracic 2Breast 2Lymphoid 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 7Colorectal Neoplasms 7Carcinoma, Renal Cell 7Neoplasms 6Lymphoma, Non-Hodgkin 6Carcinoma, Non-Small-Cell Lung 6Uterine Cervical Neoplasms 4Prostatic Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Carcinoma, Merkel Cell 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Neoplasm Metastasis 3Multiple Myeloma 3Head and Neck Neoplasms 3Carcinoma, Transitional Cell 3Small Cell Lung Carcinoma 2Skin Neoplasms 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Hematologic Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2

Interventions

pembrolizumab 72Cisplatin 57Cetuximab 38Fluorouracil 25Nivolumab 21Radiotherapy 20Carboplatin 19Paclitaxel 14Docetaxel 11Cyclophosphamide 9Gefitinib 8fludarabine 7durvalumab 7zalutumumab 6atezolizumab 6Drug Therapy 6Bleomycin 6epacadostat 5cemiplimab 5Radiotherapy, Intensity-Modulated 5Pemetrexed 5Ipilimumab 5Gemcitabine 5Afatinib 5spartalizumab 4Standard of Care 4Radiation 4Injections 4Immune Checkpoint Inhibitors 4Fibroblast Growth Factor 7 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Head and Neck Neoplasms × Interleukin-2 × Clear all
NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
5 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT05122221 2022-06-28

CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers

Corregene Biotechnology Co., Ltd

Phase 1 Unknown
12 enrolled
GastrointestinalGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡